Moreover, the 36-month beta value for INAB is -0.01. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for INAB is 2.70M and currently, short sellers hold a 9.01% of that float. On July 10, 2025, INAB’s average trading volume was 183.25K shares.
INAB) stock’s latest price update
IN8bio Inc (NASDAQ: INAB)’s stock price has gone rise by 13.18% in comparison to its previous close of $2.2, however, the company has experienced a 20.29% increase in its stock price over the last five trading days. globenewswire.com reported 2025-06-09 that NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced that Patient 009 in the Phase 1 trial of INB-200 for newly-diagnosed GBM has recently reached a significant clinical milestone. The patient, with a grade 4, IDH-mutant glioma, has been in remission and surviving for 4 years having been treated with INB-200.
INAB’s Market Performance
IN8bio Inc (INAB) has experienced a 20.29% rise in stock performance for the past week, with a -40.29% drop in the past month, and a -43.99% drop in the past quarter. The volatility ratio for the week is 7.08%, and the volatility levels for the past 30 days are at 8.22% for INAB. The simple moving average for the past 20 days is 10.79% for INAB’s stock, with a -63.86% simple moving average for the past 200 days.
Analysts’ Opinion of INAB
Many brokerage firms have already submitted their reports for INAB stocks, with Laidlaw repeating the rating for INAB by listing it as a “Buy.” The predicted price for INAB in the upcoming period, according to Laidlaw is $7.50 based on the research report published on March 18, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see INAB reach a price target of $14. The rating they have provided for INAB stocks is “Buy” according to the report published on August 30th, 2022.
INAB Trading at -29.61% from the 50-Day Moving Average
After a stumble in the market that brought INAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.88% of loss for the given period.
Stock Fundamentals for INAB
The total capital return value is set at -1.62. Equity return is now at value -174.66, with -120.77 for asset returns.
Based on IN8bio Inc (INAB), the company’s capital structure generated 0.24 points at debt to capital in total, while cash flow to debt ratio is standing at -4.53.
Currently, EBITDA for the company is -27.78 million with net debt to EBITDA at 0.31. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.30.
Conclusion
To wrap up, the performance of IN8bio Inc (INAB) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
